An orally available mesylate salt form of the etexilate prodrug of dabigatran, a benzimidazole and direct thrombin inhibitor with anticoagulant activity. Upon administration, dabigatran etexilate is hydrolyzed by esterases and is converted into dabigatran. Dabigatran reversibly binds to and inhibits the activity of thrombin, a serine protease that converts fibrinogen into fibrin. This disrupts the coagulation cascade and inhibits the formation of blood clots. Check for active clinical trials using this agent. (NCI Thesaurus)